SuperworthAbsci price to sales ratio ABSI
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- a sliver of sales
- Last meaningful
- 196×
- Apr 2026
- 5-year median
- 76.6×
- 5-year range
- 13.2× to 196×
- Peer median
- 6.9×
Absci's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.
It was last meaningful in Apr 2026, at 196×.
On the days it had one over the last 5 years, its median was 76.6×, from 13.2× in Oct 2023 to 196× in Apr 2026.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 196× | 127× | 196× |
| 2025 | 191× | 64.0× | 194× |
| 2024 | 75.6× | 45.7× | 157× |
| 2023 | 56.3× | 13.2× | 56.3× |
| 2022 | 34.4× | 34.4× | 171× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Absci's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ABSIAbsci | n/m |
| CDNACareDx | 7.8× |
| VCYTVeracyte | 6.9× |
| BLLNBillionToOne | 12.8× |
| NRCNRC Health | 3.5× |
| LNTHLantheus | 4.2× |
| CAICaris Life Sciences | 9.1× |
| BIOBio-Rad Laboratories | 3.8× |
| Peer median | 6.9× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Absci
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.